

INVESTOR LETTER, AUGUST 1 2025

Record-high global interest in Prolight's point-of-care system Psyros™ at the recently concluded ADLM Congress in Chicago, USA

Dear shareholders,

At the international ADLM (Association for Diagnostics & Laboratory Medicine) congress, Prolight showcased for the first time a fully functioning commercial prototype of its proprietary and patent-protected point-of-care (POC) system, Psyros.

The small, portable commercial prototype, featuring powerful, innovative POC technology and a user-friendly design was very well received. The response from both the potential commercial partners we are already in discussions with, as well as from new international stakeholders we connected with during the congress, was overwhelmingly positive. Everyone was highly impressed by Psyros' performance, with its ability to deliver high sensitivity results combined with its sleek compact look, intelligent features and very competitively priced consumable cartridge.



Attending the congress were, from left: CEO Ulf Bladin, Senior Scientist Karl Campany, Head of Engineering Paul Monaghan, CTO Steve Ross (holding the Psyros instrument), and COO Karl Bullen.

After the summer break, these discussions will be elevated to the next level with the aim of accelerating and ensuring an optimal global launch of Psyros in collaboration with one or more well-established international partners. In parallel, our team continues its focused efforts to finalize and optimize the system, including verification and validation ahead of the upcoming clinical regulatory performance study for EU approval (IVDR).

We wish all our shareholders a continued relaxing and enjoyable summer!

Ulf Bladin, CEO Prolight Diagnostics